Изменение уровней экспрессии генов из критичных районов хромосомы 3 человека в эпителиальных опухолях разных локализаций
Диссертация
В отличие от протеинов молекулы РНК и ДНК стабильны и для их выявления необходимо экстремально малое количество биологического материала. Известно, что первичный дефект при раке возникает в геномной ДНК, и одной из форм проявления этих дефектов является изменение уровня экспрессии гена, в котором произошли генетические или эпигенетические изменения, затрагивающие структуру гена, в том числе его… Читать ещё >
Список литературы
- Абелев Г. И., Эрайзер Т. JI. На пути к пониманию природы рака. Обзор. Биохимия, 2008, 73(5), 605−618.
- Белохвостов А.С., Румянцев А. Г. Онкомаркеры. Требования к онкомаркерам и области применения трех типов онкомаркеров. Москва, 2003а, 6−7.
- Белохвостов А.С., Румянцев А. Г. Онкомаркеры. Молекулярно-генетические онкомаркеры и методы их определения. Москва, 20 036, 7−42.
- Брага Э. А., Кашуба В. И., Малюкова А. В. и др. Новые гены-супрессоры опухолевого роста в горячих точках хромосомы 3 человека: новые методы идентификации. Молекулярная биология. 2003, 37(2), 194−211.
- Брага Э. А., Киселев JI. JL, Забаровский Е. Р. От идентификации геномного полиморфизма к диагностическим и прогностическим маркерам эпителиальных опухолей человека. Молекулярная биология. 2004, 38(2), 179−190
- Ванюшин Б.Ф. Метилирование ДНК и эпигенетика. Генетика, 2006, 42(9), 1186— 1199.
- Немцова М.В., Залетаев Д. В., Стрельников В. В., Бабенко О. В., Васильев Е. В., Землякова В. В., Жевлова А. И., Дрозд О. В. Диагностика эпигенетической патологии при наследственных и онкологических заболеваниях. Молекулярная биология, 2004, 38(2), 213−223
- Зборовская И.Б. 2000. Молекулярно-биологические исследования онкогенов и генов-супрессоров опухолевого роста в клинической практике. Сборник обзорных статей «Канцерогенез», под ред. Д. Г. Заридзе. М.: Научн. Мир, 361−379.
- Киселев JI. JL, Сенченко В. Н., Опарина Н. Ю. и др. Гены-супрессоры опухолевого роста, локализованные на коротком плече хромосомы 3 человека. Молекулярная медицина. 2005, 3, 17−28.
- Киселев ФЛ. Гены стабилизации ДНК и канцерогенез. Молекулярная биология, 1998, 32, 197−205.
- Киселева Н.П., Киселев Ф. Л. Деметилирование ДНК и канцерогенез (обзор) Биохимия, 2005, 70, 900−912.
- Кленов М.С., Гвоздев В. А. Биохимия, 2005, 70, 1445−1458.
- Копнин Б.П. 2000.0пухолевые супрессоры и мутаторные гены. Сборник обзорных статей «Канцерогенез», под ред. Д. Г. Заридзе, М: Научн. мир, стр. 75−92.
- Лихтенштейн А.В., Потапова Г. И. Генетические дефекты как маркеры опухолевого роста. Молекулярная биология, 2003, 37, 181−193.
- Пронина И.В., Логинов В. И., Прасолов B.C., Климов Е. А., Ходырев Д. С., Казубская Т. П., Гарькавцева Р. Ф., Сулимова Г. Е., Брага Э. А. Изменение уровней экспрессии гена SEMA3B в эпителиальных опухолях. Молекулярная биология. 2009, 43(3), 429−435.
- Пфайфер Г. П., Дамманн Р. Метилирование гена опухолевого супрессора RASSFIA в человеческих опухолях. Биохимия. 2005, 70(5), 699−708.
- Рогаев Е.И., Боринская С. А., Исламгулов Д. В., Григоренко А. П. МикроРНК человека в норме и патологии. 2008, Молекулярная биология, 42(5), 751−764.
- Ровенский Ю.А. и Васильев Ю.М. Морфогенетические реакции клеток и их нарушения при опухолевой трансформации. 2000. Сборник обзорных статей «Канцерогенез», под ред. Д. Г. Заридзе, М: Научн. Мир, стр. 260−283.
- Рязанский С.С., Гвоздев В. А. Короткие РНК и канцерогенез. 2008, Биохимия, 73(5), 640−655
- Татосян А.Г. 2000. Онкогены. Сборник обзорных статей «Канцерогенез», под ред. Д. Г. Заридзе, М: Научн. Мир, стр. 57−74.
- Чумаков П.М. Роль р53 в программируемой клеточной смерти. Изв. Акад. Наук, сер. Биология, 1998, 2, 151−156.
- Чумаков П.М. Функция генар53: выбор между жизнью и смертью. Биохимия, 2000, 65, 28−40.
- Allis C.D., Junewein Т., Reinberg D., Capparos M.L. Epigenetics, 2006, CSHL Press, N.Y.
- Alvarez-Garcia I., Miska E.A., MicroRNA functions in animal development and human disease, Development 132. 2005, 4653−4662.
- Angeloni D., Ter Elst A., Wei M. H. et al. Analysis of a new homozygous deletion in the tumor suppressor region at 3pl2.3 reveals two novel intronic noncoding RNA genes. Genes Chromosomes Cancer. 2006, 45(7), 676−691.
- Apicelli AJ, Uhlmann EJ, Baldwin RL, Ding H, Nagy A, Guha A, Gutmann DH. Role of the Rapl GTPase in astrocyte growth regulation. Glia, 2003, 42, 225−234.
- Assoian RK. Stopping and going with p27kipl. Dev Cell., 2004, 6(4), 458−459.
- Attwood JT, Yung RL, Richardson ВС. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci., 2002, 59, 241−257.
- Avraham H., Weinberg R.A. 1989. Characterization and expression of the human rhoH12 gene product. Mol. Cell Biol., 9, 2058−2066.
- Bartel D.P. Cell, 2004, 116, 281−297
- Bateman A., Birney E., Durbin R., Eddy S.R., Finn R.D. and Sonnhammer E.L. Pfam 1313 multiple alignments and profile HMMs match the majority of proteins. Nucleic Acids Res., 1999,27,260−262.
- Batinac T, Gruber F, Lipozencic J, Zamolo-Koncar G, Stasic A, Brajac I. Protein p53 -Structure, Function, and Possible Therapeutic Implications. Acta Dermatovenerol Croat., 2003, 11, 225−230.
- Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al., DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005, 434, 864−870.
- Baylin SB. Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol. 2002, 12, 331−337.
- Baylin SB, Herman JG, Graf JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 1998, 72, 141−196.
- Bell DR, Van Zant G. Stem cells, aging, and cancer: inevitabilities and outcomes. Oncogene. 2004, 23(43), 7290−7296.
- Benezra M, Chevallier N, Morrison DJ, MacLachlan TK, El-Deiry WS, Licht JD. BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J. Biol. Chem., 2003, 278, 26 333−26 341.
- Berezikov E., Plasterk R.H., Camels and zebrafish, viruses and cancer: a microRNA update. Hum. Mol. Genet. 2005,14, R183-R190.
- Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer. 2005, 5(11), 899−904.
- Bird AP. DNA methylation patterns and epigenetic memory. Genes Dev., 2002, 16, 6−21. Bird A. Nature, 2007, 447, 396−398.
- Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J. Qin Z.S., Moore B.B., Macdougald O.A. Cho K.R. and Fearon E.R. Curr.Biol., 2007, 17, 1298−1307.
- Boudeau J, Sapkota G, Alessi DR. LKB1, a protein kinase regulating cell proliferation and polarity. FEBSLett., 2003, 546, 159−65.
- Cahill D.P., Kinzler K.W., Vogelstein В., Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 1999 9, M57-M60.
- Calin G.A., Ferracin M., Cimmino A. MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N.Engl. J.Med. 2005, 353, 1793−1801.
- Castro-Rivera E., Ran S., Thorpe P., Minna J.D. Semaphorin 3B {SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF 165 antagonizes this effect. Proc Natl Acad Sci USA, 2004,101, 11 432−11 437.
- Chambon P.A. Decade of molecular biology of retinoic acid receptors. FASEB J., 1996. 10, 940−954.
- Chang T.C., Wentzel E.A., Kent O.A. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 2007, 26, 745−752.
- Chen Y., Vallee S., Wu J., et al. Inhibition of NF-kappaB activity by IkappaBbeta in association with kappaB-Ras. Mol. Cell. Biol., 2004, 24, 3048−3056.
- Chen S, Paul P, Price BD. ATM’s leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response. Oncogene, 2003, 22, 63 326 339.
- Chen C.Z., Lodish H.F. MicroRNAs as regulators of mammalian hematopoiesis. Semin. Immunol. 2005,17, 155−165.
- Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005, 33, 1290−1297.
- Choi C.H., Lee K.-M., Choi J.J. et al. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Letters, 2007, 255, 26−33.
- Chou C.H., Lee K.-M., Choi J.J., Kim T.-J., Kim W.Y., Lee J.-W., Lee S.-J., Lee J.-H., Bae D.-S., Kim B.-G. Hypermethylation and loss of heterozygosity of tumor supressor genes on chromosome 3p in cervical cancer. Cancer Lett., 2007 255, 26−33.
- Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J Clin Invest. 2002 109, 857−862. (Review)
- Conover W.J. (1980). Practical Nonparametric Statistics. 2nd. ed. New York: Wiley
- Corral T, Jimenez M, Hernandez-Munoz I, Perez de Castro I, Pellicer A. NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity. J. Cell Physiol., 2003,197, 214−24.
- Costello JF, Plass C. Methylation matters. J. Med. Genet., 2001, 38, 285−303.
- Cote S., Sinnett D., Momparler R.L. Demethylation by 5-aza-2-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs., 1998, 9, 743−50.
- Dammann R., Li C., Yoon J.H., Chin P.L., Bates S. and Pfeifer G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet., 2000, 25, 315−319.
- Das P.M. and Singal R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22, 46 324 642.
- Dasgupta B, Dugan LL, Gutmann DH. The neurofibromatosis 1 gene product neuroflbromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. JNeurosci., 2003, 23, 8949−8954.
- Dikovskaya D, Zumbrunn J, Penman GA, Nathke IS. The adenomatous polyposis coli protein: in the limelight out at the edge. Trends Cell Biol., 2001, 11, 378−384
- Diwadkar-Navsariwala V, Diamond AM. The link between selenium and. chemoprevention: a case for selenoproteins. J. Nutr., 2004, 134, 2899−2902.
- Dodge JE, List AF, Futscher BW. Selective variegated methylation of the pl5 CpQ-island in acute myeloid leukemia. Int. J. Cancer, 1998, 78, 561−567.
- Dowsett M., Daffada A., Chan C.M., Johnston S.R. Oestrogen receptor mutants and variants in breast cancer. Eur. J. Cancer, 1997, 33, 1177−1183.
- Eden A. Chromosomal instability and tumors promoted by DNA hypomethylation. Science, 2003, 18, 300:455
- Esquuela-Kerscher A. and Slack F.J. Nat.Rev.Cancer, 2006, 6, 259−269
- Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet., 2007,16(Spec No 1), R50−59.
- Esteller M., Herman J.G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol., 2002, 196, 1−7.
- Etienne-Manneville S., Hall A. Rho GTPases in cell biology. Nature, 2002, 420, 629-. 635.
- Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001 411, 342−348
- Faucher K., Rabinovitch-Chable H., Barriere G., Cook-Moreau J., Rigaud lyj Overexpression of cytosolic glutathione peroxidase (GPX1) delays endothelial cell growth and increases resistance to toxic challenges. Biochimie, 2003, 85, 611−617.
- Feinberg AP. Imprinting of a genomic domain of 1 lpl5 and loss of imprinting in cancer- an introduction. Cancer Res., 1999, 59, 1743−1746.
- Feinberg AP, Oshimura M, Barrett JC. Epigenetic mechanisms in human disease. Cancer Res., 2002, 62(22), 6784−6787.
- Fenwick C., Na S.Y., Voll R.E. A subclass of Ras proteins that regulate the degradation of IkappaB. Science, 2000, 287, 869−873.
- Fernandez H.R. Heterochromatin: on the ADAR radar? Curr. Biol., 2005, 15, R132-R134.
- Fritz G., Brachetti C., Bahlmann F., Schmidt M., Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br. J. Cancer, 2002, 87, 635−644.
- Fritz G., Just I., Kaina B. Rho GTPases are over-expressed in human tumors. Int. J. Cancer, 1999,819,682−687.
- Fukuhara N., Ebert J., Unterholzner L., Lindner D., Izaurralde E., Conti E. SMG7 is a 14−3-3-like adaptor in the nonsense-mediated mRNA decay pathway. Mol. Cell, 2005, 17, 537−547.
- Garcia P., Manterola C., Araya J.C., Villaseca M., Guzman P., Sanhueza A., Thomas M., Alvarez H., Roa J.C. Mol Carcinog., 2009, 48(1), 79−89.
- Gehring N.H., Kunz J.B., Neu-Yilik G., Breit S., Viegas M.H., Hentze M.W., Kulozik A.E. Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements. Mol. Cell, 2005, 20, 65−75.
- Gerber A.P., Keller W. RNA editing by base deamination: more enzymes, more targets, new mysteries. Trends Biochem. Sci., 2001, 26, 376−384.
- Glenn ST, Jones CA, Liang P, Kaushik D, Gross KW, Kim HL. Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. Biotechniques. 2007, 43(5), 639−640.
- Green D.R. Apoptotic pathways: the roads to ruin. Cell, 1998, 94, 695−698 (Review).
- Green D.R. Apoptotic pathways: paper wraps stone blunts scissors. Cell, 2000 102, 1−4. (Review).
- Green R.E., Lewis B.P., Hillman R.T., Blanchette M., Lareau L.F., Garnett A.T. et al. Widespread predicted nonsense-mediated mRNA decay of alternatively-spliced transcripts of human normal and disease genes. Bioinformatics, 2003, 19, il 184 121.
- Greider C.W. Telomerase activity, cell proliferation, and cancer. Proc.Natl.Acad. Sci. USA, 1998, 95, 90−92 (Review).
- Hall A. Rho GTPases and the actin cytoskeleton. Science, 1998, 279, 509−514.
- Hanahan D, Weinberg R.A. Rules for making human tumor cells. N. Engl. J. Med. 2002, 347, 1593−1603. (Review)
- Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell, 2000, 100, 57−70 (Review).
- Hansen S, Lane DP, Midgley CA. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability. J Mol Biol., 1998, 275, 575−588.
- Hasegawa Y., Takano Т., Miyauchi A., Matsuzuka F., Yoshida H., Kuma K., Amino N. Decreased expression of glutathione peroxidase mRNA in thyroid anaplastic carcinoma. Cancer Lett., 2002,182, 69−74.
- He L., He X., Lim L.P. A microRNA component of the p53 tumor suppressor network. Nature, 2007, 447, 1130−1134.
- Hesson L.B., Cooper W.N., LatifF. 2007. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene, 26, 7283−7301.
- Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci., 2003, 94, 575−581. (Review)
- Holbrook J. A, Neu-Yilik G, Hentze M. W, Kulozik A.E. Nonsense-mediated decay approaches the clinic Nat. Genet., 2004, 36, 801−808.
- Homma MK, Li D, Krebs EG, Yuasa Y, Homma Y. Association and regulation of casein kinase 2 activity by adenomatous polyposis coli protein. Proc Natl Acad Sci USA., 2002, 99, 5959−64.
- Hong W.K., Lippman S.M., Hittelmann W.N. and Lotan R. Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic. Clin. Cancer Res., 1995, 1, 677 686.
- Horiuchi A., Imai Т., Wang C., Ohira S., Feng Y., Nikaido Т., Konishi I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab. Invest., 2003, 83, 861−870.
- Hsu H.-S., Chen T.-P., Hung Ch.-H. et al. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer, 2007,110, 2019−2026.
- Hu Y.J., Diamond A.M. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res., 2003, 63, 3347−3351
- Jain PK. Epigenetics: the role of methylation in the mechanism of action of tumor suppressor genes. Ann N YAcad Sci., 2003, 983, 71−83.
- Jannot G. and Simard M.J. Oncogene, 2006, 25, 6197−6201.
- Jay C., Nemunaitis J., Chen P., Fulgham P., and Tong A.W. DNA Cell Biol., 2007, 26, 293−300.
- Jenuwein T. Molecular biology, an RNA-guided pathway for the epigenome. Science, 2002,297, 2215−2218.
- Jones PA and Laird PW. Cancer epigenetics comes of age. Nature Genet., 1999, 21, 163 170.
- Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A. et al. RAS is regulated by the let-7 microRNA family. Cell, 2005, 120, 635−647.
- Kalnina Z., Zayakin P., Silina K., Line A. Alterations of premRNA splicing in cancer. Genes Chromosomes Cancer, 2005, 42, 342—357.
- Kamai Т., Arai K., Tsujii Т., Honda M., Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumor. BJU Int., 2001, 87, 227 231.
- Kamai Т., Kawakami S., Koga F., Arai G., Takagi K., Arai K., Tsujii Т., Yoshida K.I. RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer. BJU Int., 2003a, 91, 234−238.
- Kamai Т., Tsujii Т., Arai K., Takagi K., Asami H., Ito Y., Oshima H. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res., 20 036., 9, 2632−2641.
- Kamai Т., Yamanishi Т., Shirataki H., Takagi K., Asami H., Ito Y., Yoshida K. Overexpression of RhoA, Racl, and Cdc42 GTPases is associated with progression in testicular cancer. Clin. Cancer Res., 2004, 10, 4799−4805.
- Kang W.K., Lee I., Ко U., Park C. Differential effects of RhoA signaling on anticancer agent-induced cell death. Oncol. Rep., 2005,13, 299−304.
- Kashuba VI, Pavlova TV, Grigorieva EV, Kutsenko A, Yenamandra SP, Li J, Wang F, Protopopov Al, Zabarovska VI, Senchenko V, Haraldson K, Eshchenko T, Kobliakova J,
- Vorontsova О, Kuzmin I, Braga E, Blinov VM, Kisselev LL, Zeng YX, Ernberg I, Lerman MI, Klein G, Zabarovsky ER High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer. PLoS One. 2009, 4(5), e5231.
- Karube Y., Tanaka H., Osada H., Tomida S., Tatematsu Y., Yanagisawa K. et al., Reduced expression of dicer associated with poor prognosis in lung cancer patients, Cancer Sci., 2005, 96, 111−115.
- Kataoka N., Yong J., Kim V. N, Velazquez F., Perkinson R.A., Wang F., Dreyfuss G. Pre-mRNA splicing imprints mRNA in the nucleus with a novel RNA-binding protein that persists in the cytoplasm., Mol. Cell, 2000, 6, 673−682.
- Kawasaki H., Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature, 2004, 431, 211−217.
- Kawasaki H., Taira K., Morris К. V. siRNA induced tran scriptional gene silencing in mammalian cells. Cell Cycle, 2005, 4, 442−448.
- Keshet I, Schlesinger Y, Farkash S, Rand E, Hecht M, Segal E, Pikarski E, Young RA, Niveleau A, Cedar H, Simon I. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet., 2006, 38(2), 149−153.
- Kim V.N. Nat.Rev.Mol.CellBiol., 2005, 6, 376−385
- Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer .J Clin Oncol., 2004, 22, 4991−5004.
- Kim YI, Giuliano A, Hatch KD, Schneider A, Nour MA, Dallal GE, Selhub J, Mason JB. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer., 1994, 74, 893−899.
- Kinzler KV, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers (news, comment). Nature, 1997, 386, 761−763
- Knight J. Cancer comes under scrutiny in fresh genomics initiative, Nature, 2001, 410, 855,
- Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res., 1985, 45, 1437−1443.
- Кок K, Naylor SL, Buys CHCM. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv. Cancer Res., 1997, 71, 27
- Korotkina RN, Matskevich GN, Devlikanova ASh, Vishnevskii AA, Kunitsyn AG, Karelin AA. Activity of glutathione-metabolizing and antioxidant enzymes in malignant and benign tumors of human lungs. Bull Exp Biol Med., 2002, 133, 606−608.
- Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene., 2002, 21, 2357−2364.
- Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Williams NN, Kaiser LR and Croce CM. Allelic Loss on Chromosome 3p21.3 and Promoter Hypermethylation of Semaphoring in Non-Small Cell Lung Cancer. Cancer Res., 2003, 63, 3352−3355.
- J., Gets G., MiskaE.A., Varez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Мак R.H., Ferrando A.A., Downing J.R., Jacks Т., Horvitz H.R., and Golub T.R. Nature, 2005, 435, 834−838.
- McGregor F., Muntoni A., Fleming J. et al. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Res., 2002, 62, 4757−66.
- Maquat L.E. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat. Rev. Mol. Cell Biol., 2004, 5, 89−99.
- Maliekal TT, Antony ML, Nair A, Paulmurugan R, Karunagaran D. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene, 2003, 22, 4889−4897.
- Masuda A, Kamai T, Abe H, Arai K, Yoshida K. Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma? Biomed Res., 2009, 30(3), 171−176.
- Mattick J.S. RNA regulation: a new genetics? Nat. Rev. Genet. 2004, 5, 316−323.
- Michael M.Z., O’Connor S.M., van Hoist Pellekaan N.G., Young G.P., and James RJ. Mol.CancerRes., 2003, 1, 882−891.
- Miralem T, Avraham HK Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its С terminus. Mol Cell Biol., 2003,23, 579−593.
- Miyakura Y, Sugano K, Konishi F, Fukayama N, Igarashi S, Kotake K, Matsui T, Koyama Y, Maekawa M, Nagai H. Methylation profile of the MLH1 promoter region and their relationship to colorectal carcinogenesis. Genes Chromosomes Cancer, 2003, 36, 17−25.
- Moren A, Hellman U, Inada Y, Imamura T, Heldin CH, Moustakas A. Differential ubiquitination defines the functional status of the tumor suppressor Smad4. J Biol Chem., 2003,278, 33 571−33 582.
- Moscow J.A., He R., Gnarra J.R., Knutsen Т., Weng Y., Zhao W.P., Whang-Peng J., Linehan W.M., Cowan K.H. Examination of human tumors for rhoA mutations. Oncogene, 1994, 9, 189−194.
- Murrell A., Rakyan V.K., Beck S. From genome to epigenome. Hum. Mol. Genet., 2005, 14, R3-R10.
- Morris K.V. siRNA-mediated transcriptional gene silencing: the potential mechanism and a possible role in the histone code. Cell Mol. Life Sci., 2005, 62, 3057−3066.
- Morris K.V., Chan S.W., Jacobsen S.E., Looney D.J. Small interfering RNA-induced transcriptional gene silencing in human cells. Science, 2004, 305, 1289−1292.
- Na X, Duan HO, Messing EM, Schoen SR, Ryan CK, di Sant’Agnese PA, Golemis EA, Wu G. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBOJ., 2003, 22, 4249−4259.
- Nakamoto M., Teramoto H., Matsumoto S., Igishi Т., Shimizu E. K-ras and rhoA mutations in malignant pleural effusion. Int. J. Oncol., 2001, 19, 971−976.
- Nakayama Т., Watanabe M., Yamanaka M. et al. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab. Invest., 2001, 81, 1049−57.
- Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, Ehrlich M. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer., 1998, 77, 833−838.
- Nilsen T. W. The spliceosome: the most complex macromolecular machine in the cell? Bioessays, 2003, 25, 1147−1149.
- Ochi К., Mori Т., Toyama Y., Nakamura Y., Arakawa H. Identification of semaphorin3B as a direct target of p53. Neoplasia, 2002, 4, 82−87.
- O’Dnnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., and Mendell J.T. Nature, 2005, 435, 839−843
- Ohtani N, Yamakoshi K, Takahashi А, Нага E. The pl6INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest. 2004, 51(3−4), 146−153.
- Onay H., Pehlivan S., Koyuncuoglu M., Kirkali Z., Ozkinay F. Multigene methylation analysis of conventional renal cell carcinoma. Urol Int., 2009, 83(1), 107−12
- O’Neill M.J. The influence of non-coding RNAs on allelespecific gene expression in mammals. Hum. Mol. Genet., 2005, 14, R113-R120.
- O’Rourke J.R., Swanson M.S., and Harfe B.D. Birth Defects Res.C.Embryo.Today., 2006, 78, 172−179.
- Orphanides G., Reinberg D. A unified theory of gene expression. Cell, 2002,108, 439 451.
- Pandolfl P.P. Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age. Oncogene, 2004, 23, 3134−3137.
- Pang K.C., Stephen S., Engstrom P.G., Tajul-Arifin K., Chen W., Wahlestedt C. et al., RNAdb -a comprehensive mammalian noncoding RNA database. Nucleic Acids Res., 2005, 33, D125-D130.
- Pan Y., Bi F., Liu N., Xue Y., Yao X., Zheng Y., Fan D. Expression of seven main Rho family members in gastric carcinoma. Biochem. Biophys. Res. Commun., 2004, 315, 686 691.
- Parker R., Song H. The enzymes and control of eukaryotic mRNA turnover. Nat. Struct. Mol. Biol., 2004,11, 121−127.
- Paterson H.F., Self A.J., Garrett M.D., Just I., Aktories K., Hall A. Microinjection of recombinant p21rho induces rapid changes in cell morphology. J. Cell Biol., 1990, 111, 1001−1007.
- Perrin-Vidoz L., Sinilnikova O.M., Stoppa-Lyonnet D., Lenoir G.M., Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum. Mol. Genet., 2002, 11, 2805−2814.
- Ponder BAJ. Cancer genetics. Nature, 2001, 411, 336−341.
- Qu GZ, Dubeau L, Narayan A, YuMC, Ehrlich M. Satellite DNA hypomethylation vs overall genomic hypomethylation in ovarian epithelial tumors of diVerent malignant potential. Mutat Res Fund Mol Mech Mutagens., 1999, 423, 91−101
- Raschle M, Dufner P, Marra G, Jiricny J. Mutations within the hMLHl and hPMS2 subunits of the human MutL-alpha mismatch repair factor affect its ATP-ase activity, but not its ability to interact with hMutS-alpha. J Biol Chem., 2002, 277, 21 810−21 820.
- Raver-Shapira N., andOren M. Cell Cycle, 2007, 6, 2656−2661.
- Rihet S., Vielh P., Camonis J., Goud В., Chevillard S., de Gunzburg J. Mutation status of genes encoding RhoA, Racl, and Cdc42 GTPases in a panel of invasive human colorectal and breast tumors. J. Cancer Res. Clin. Oncol., 2001, 127, 733−738.
- Roberts R.G., Gardner R.J., Bobrow M. Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum. Mutat., 1994, 4, 1−11.
- Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet., 2000, 1, 11−19.
- Roche J., Drabkin H.A. The role of semaphorins in lung cancer. Clin Lung Cancer, 2001, 3, 145−150.
- Saaristo A., Karpanen Т., Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene, 2000, 19, 6122−6129. (Review)
- Sahai E., Marshall C.J. Rho-GTPases and cancer. Nature Rev., 2002, 2, 133−142.
- Sanchez-Garcia I. Consequences of chromosomal abnormalities in tumor development. AnnuRev Genet., 1997, 31, 429−453.
- Scholzova E, Malik R, Sevcik J, Kleibl Z. RNA regulation and cancer development. Cancer Lett. 2007, 246, 1−2: 12−23.
- Seeburg P.H., Higuchi M., Sprengel R. RNA editing of brain glutamate receptor channels: mechanism and physiology. Brain Res. Brain Res. Rev., 1998, 26, 217−229.
- Shabalina S.A., Spiridonov N.A. The mammalian transcriptome and the function of non-coding DNA sequences. Genome Biol., 2004, 5, 105.
- Sherr C.J. The pezcoller lecture: cancer cell cycles revisited. Cancer Res., 2000, 60, 3689−3695.
- Shin S, Verma IM. BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. Proc Natl Acad Sci USA., 2003,100, 7201−7206.
- Shivakumar L., Minna J., Sakamaki Т., Pestell R., White M.A. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol., 2002, 22, 4309−4318
- Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolo G, Sacchi N. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res., 2002, 62(9), 2455−2461.
- Stamm S., Ben Ari S., Rafalska I., Tang Y., Zhang Z., Toiber D. et al. Function of alternative splicing. Gene, 2005, 344, 1−20.
- Stoneley M., Willis A.E. Aberrant regulation of translation initiation in tumorigenesis. Curr. Mol. Med., 2003, 3, 597−603.
- Stunnenberg, H.G., Garcia-Jimenez, C., and Betz J.L. Leukemia: the sophisticated subversion of hematopoiesis by nuclear receptor oncoproteins. Biochim. Biophys. Acta, 1999,1423, 15−33. (Review)
- Su GH, Song JJ, Repasky EA, Schutte M, Kern SE. Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat., 2002,19, 81.
- Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res., 2004, 64, 3753−3756.
- Tan M., Li S., Swaroop M., Guan K., Oberley L.W., Sun Y. Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem., 1999, 274, 1 206 112 066.
- Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem. Sci., 2005, 30, 106−114.
- Tarasov V., Jung P., Verdoodt В., Lodygin D., Epanchintsev A., Menssen A., Meister G. and Hermeking H. Cell Cycle, 2007, 6, 1586−1593.
- Tomari Y., ZamoreP.D. Perspective: machines for RNAi. Genes Dev., 2005,19, 517— 529.
- Tommasi S., Dammann R., Zhang Z., Wang Y., Liu L., Tsark W.M., Wilczynski S.P., Li J., You M., Pfeifer G.P. Tumor susceptibility of Rassfla knockout mice. Cancer Res., 2005, 65, 92−98.
- Tomlinson IP. M, Novelli MR, Bodmer WF. The mutation rate and cancer. Proc. Natl. Acad. Sci. USA., 1996, 93, 14 800−14 803.
- Trusolino L. and Comoglio P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Reviews Cancer, 2002, 2, 289−300.
- Tse C., Xiang R.H., Bracht T. and Naylor S.L. Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res., 2002, 62, 542−546.
- Vachtenheim J, Horakova I, Novotna H. Hypomethylation of CCGG sites in the 3' region of H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. Cancer Res., 1994, 54, 1145−1148.
- Vial E., Sahai E., Marshall С.J. ERK-MAPK signaling coordinately regulates activity of Racl and RhoA for tumor cell motility. Cancer Cell, 2003, 4, 67−69.
- Vidal A., Millard S.S., Miller J.P., Koff A. Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status. J. Biol. Chem., 2002, 277, 16 433−16 440.
- Virmani AK, Muller C, Rathi A, Zoechbauer-Muleller S, Mathis M, Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res., 2001, 7, 584−589
- Vogelstein В., Kinzler K. Cancer genes and the pathways they control. Nature Medicine, 2004,10, 789−799.
- Vos M.D., Ellis C.A., Bell A., Birrer M.J. and Clark G.J. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem., 2000, 275, 35 669−35 672.
- Waki T, Tamura G, Sato M, Motoyama T. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene, 2003, 22, 41 284 133.
- Wang F, Grigorieva EV, Li J, Senchenko VN, Pavlova TV, Anedchenko EA, Kudryavtseva AV, Tsimanis A, Angeloni D, Lerman MI, Kashuba VI, Klein G, Zabarovsky ER. HYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitro. PLoS One., 2008, 3(8), e3031.
- Widschwendter M., Berger J., Muller H.M. et al. Epigenetic downregulation of the retinoic acid receptor-(32 gene in breast cancer. J. Mam. Gl. Biol and Neop., 2001, 6. 193−201.
- Wilkinson M.F. A new function for nonsense-mediated mRNA-decay factors. Trends Genet., 2005, 21, 143−148.
- Wilkinson M.F., Shyu A.B. RNA surveillance by nuclear scanning? Nat. Cell Biol., 2002, 4, E144-E147.
- Wilusz C.J., Wormington M., Peltz S.W. The cap-to-tail guide to mRNA turnover. Nat. Rev. Mol Cell Biol., 2001, 2, 237−246.
- Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, Mackay B, Minna JD, Gazdar AF. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res., 2000a, 6, 2604−2610.
- Xu P., Guo M., Hay B.A. MicroRNAs and the regulation of cell death. Trends Genet., 2004, 20, 617−624.
- Yan J, Zhu J, Zhong H, Lu Q, Huang C, Ye Q. BRCA1 interacts with FHL2 and enhances FHL2 transactivation function. FEBSLett., 2003, 553, 183−189
- Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka Т., Calin G.A., Liu C.G., Croce C.M., and Harris C.C. Cancer Cell, 2006, 9, 189−198.
- Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH, Zheng N, Chen PL, Lee WH, Pavletich NP. BRCA2 function in DNA binding and recombination from a BRCA2-DSSl-ssDNA structure. Science, 2002, 297, 1837−1848.
- Yekta S., Shih I.H., Bartel D.P. MicroRNA-directed cleavage of HOXB8 mRNA. Science, 2004, 304, 594−596.
- Yoder JA, Walsh CP, Bestor TH: Cytosine methylation and the ecology of intragenomic parasites. Trends Genet., 1997, 13, 335−340.
- Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science, 2003, 302, 639−642.
- Zabarovsky E.R., Lerman M.I., Minna J.D. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene, 2002, 21(45), 69 156 935.
- Zeng Y. Oncogene, 2006, 25, 6156−6162
- Zochbauer-Muller S, Gazdar AF and Minna JD. Molecular pathogenesis of lung cancer. Annu. Rev. Physiol., 2002, 64, 681−708.